Canadian clinical trial registry

Search results

Information is also accessible through the patient and families tab. Family friendly summaries are created and reviewed by our advocacy partners. The information is updated to the best of our knowledge but might not reflect the latest information. Note that most studies are only available at a limited number of sites, please click on ‘further information’ for details. Studies, particularly early phase trials, may also temporarily close to enrolment or not have slots available for all treatment groups. In all cases, study teams at individual C17 centres will have the most up-to-date information.

96 results found

Title
Status

 

SNDX-5613-0700 - AUGMENT-101: A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX 5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Closed to enrollment

SNDX-5613-0700 - AUGMENT-101: A Phase 1/2, Open-label, Dose-Escalation and Dose-Expansion Cohort Study of SNDX 5613 in Patients With Relapsed/Refractory Leukemias, Including Those Harboring an MLL/KMT2A Gene Rearrangement or Nucleophosmin 1 (NPM1) Mutation

Go to Health Care Provider version

DiagnosisAcute Myeloid Leukemia Acute Lymphoblastic Leukemia Mixed Lineage Acute Leukemia Mixed Phenotype Acute Leukemia Acute Leukemia of Ambiguous LineageStudy StatusClosed to enrollment
PhaseI/II
Ageup to 18 YearsRandomisationNO
Line of treatmentFirst line treatment, Disease relapse or progression
Routes of Treatment AdministrationDrug: SNDX-5613 (given orally) Drug: Cobicistat (Patients in Phase 1 Arm C patients will receive 150 mg cobicistat daily)
Last Posted Update2024-09-11
ClinicalTrials.gov #NCT04065399
International Sponsor
Syndax Pharmaceuticals
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Jim Whitlock
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

This is a phase I/II study that studies the drug SNDX-5613 in patients with acute leukemia. In phase 1, the dose will be increased to find the maximum tolerated dose of SNDX-5613 and the recommended dose for the next phase will be determined. In phase 2, patients will be given the recommended phase 2 dose determined in phase 1, and the safety and efficacy in patients with various tumour mutation will be studied. 

Inclusion Criteria
  • Patients must have active acute leukemia with certain genetic characteristics
  • Patients must be over 30 days old 
  • Patients must be up and about more than 50% of waking hours (if applicable)
  • Adequate time must have passed from all previous treatments (i.e at least 60 days must have passed from last radiation treatment/stem cell infusion (if applicable))
  • Adeqaute organ function
  • Blood work must come back within acceptable ranges
  • Patients of child bearing potential must be willing to use a highly effective method of contraception from the time of enrollment to 120 days after the last study drug dose
  • Patients and/or their families/caregivers must sign a consent form outlining all assessments and requirements

ReRAD - A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma

Closed to enrollment

ReRAD - A Phase II Canadian Pediatric Brain Tumour Consortium Study of Re-Irradiation as Treatment of Progressive or Recurrent Diffuse Intrinsic Pontine Glioma

Go to Health Care Provider version

DiagnosisRecurrent or Progressive Diffuse Intrinsic Pontine GliomaStudy StatusClosed to enrollment
PhaseII
AgeChild - (up to 17 Years)RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationPatients will receive 30.6 Gy or 36 Gy of a second course of radiation therapy for progressive or recurrent DIPG
Last Posted Update2024-09-11
ClinicalTrials.gov #NCT03126266
International Sponsor
University of Calgary
Principal Investigators for Canadian Sites
Alberta Children’s Hospital - Dr. Lucie Lafay-Cousin
Stollery Children’s Hospital - Dr. Bev Wilson
Children's Hospital of Eastern Ontario (CHEO) - Dr. Donna Johnston
Hamilton Health Sciences Centre, Mc Master University
BC Children’s Hospital – Dr. Juliette Hukin
Montreal Children's Hospital – Dr. Freeman
CHU Ste-Justine – Dr. Yvan Samson
CHU de Quebec – Dr. Samuele Renzi
Children's Hospital of Western Ontario – Dr. Shayna Zelcer
Janeway Hospital - Dr. Lynette Bowes
The Hospital for Sick Children - Dr. Ute Bartels
Centres
Medical contact
Dr. Victor Lewis

 

Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Dr. Sarah McKillop
Dr. Sunil Desai

 

 

Social worker/patient navigator contact
Danielle Sikora
 Michelle Woytiuk 
Jaime Hobbs
Clinical research contact
Amanda Perreault
Medical contact
Dr. Donna Johnston
Dr. Lesleigh Abbott
Dr. Doaa Abdel Fattah
 
Social worker/patient navigator contact
Sherley Telisma
 
Clinical research contact
Carol Duchenne
 
Medical contact
Dr. Carol Portwine
 
Social worker/patient navigator contact
Jane Cassano 
 
Clinical research contact
Sabrina Millson
 
 
Medical contact
Rebecca Deyell

 

Social worker/patient navigator contact
Ilana Katz 

 

Clinical research contact
Hem/Onc/BMT Clinical Trials Unit

 

Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 
Medical contact
Raoul Santiago
 
Social worker/patient navigator contact
Isabelle Audet
 
Clinical research contact
Barbara Desbiens
 

 

Medical contact
Dr. Alexandra Zorzi
Dr. Shayna Zelcer
 
Social worker/patient navigator contact
Cindy Milne Wren
Jessica Mackenzie Harris
 
Clinical research contact
Mariam Mikhail
Medical contact
Dr. Paul Moorehead
 
Social worker/patient navigator contact
Stephanie Eason
 
Clinical research contact
Bev Mitchell
 
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

Diffuse Intrinsic Pontine Glioma (DIPG) is an aggressive brain tumour with no effective treatment and no chance of long-term survival . When this brain tumour grows back after the initial radiation therapy, it is known as progressive or recurrent DIPG.

This study will investigate how long a second treatment with radiation (re-irradiation) keeps progressive or recurrent DIPG from growing again and the overall survival of these patients. All children enrolled will be treated with re-irradiation.

Inclusion Criteria
  • The patient is 17 years of age or younger at the time of first or second relapse or progression of disease
  • The patient has no evidence of metastases on MRI of the brain and the spine
  • The patient has received radiation in the past, given to a total dose of <60 Gy
  • At least 180 days (6 months) have elapsed from the last day of primary radiation
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

LOXO-RET-18036 (LOXO 292) - A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Closed to enrollment

LOXO-RET-18036 (LOXO 292) - A Phase 1/2 Study of the Oral RET Inhibitor LOXO 292 in Pediatric Patients With Advanced RET-Altered Solid or Primary Central Nervous System Tumors

Go to Health Care Provider version

DiagnosisSolid or brain tumour with a change in the RET geneStudy StatusClosed to enrollment
PhaseI/II
AgeChild, Adult - (6 Months to 21 Years)RandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationSelpercatinib is taken by mouth (capsules or oral suspension) Participants <18 years of age may be offered to try a tablet formulation of selpercatinib.
Last Posted Update2024-09-10
ClinicalTrials.gov #NCT03899792
International Sponsor
Loxo Oncology, Inc.
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel Morgenstern
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

This clinical trial studies the side effects and how well selpercatinib (a medication taken by mouth) works in treating patients with solid tumors and brain tumours with a change in a gene called RET. 

Selpercatinib may stop the growth of cancer cells with RET gene changes by blocking the RET enzymes needed for cell growth.

Inclusion Criteria
  • Age between 6 months and 21 years
  • Solid tumors and brain tumours with a change in a gene called RET
  • Cancer that has come back (relapse) or is not improving despite treatment (progression)
  • Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team

ACNS1831 - A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Open

ACNS1831 - A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG)

Go to Health Care Provider version

DiagnosisLow Grade Glioma, Neurofibromatosis Type 1Study StatusOpen
PhaseIII
Age2 Years to 21 YearsRandomisationYES
Line of treatmentFirst line treatment, Disease relapse or progression
Routes of Treatment AdministrationActive Comparator: Arm I (carboplatin, vincristine) Experimental: Arm II (selumetinib sulfate)
Last Posted Update2024-08-21
ClinicalTrials.gov #NCT03871257
International Sponsor
National Cancer Institute (NCI)
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Uri Tabori
Montreal Children's Hospital - Dr. Stephanie Mourad
CHU Ste Justine - Dr. Monia Marzouki
CHU Sherbrooke - Dr. Josee Brossard
IWK Health Centre - Dr. Criag Erker
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

Medical contact
Clinical Research Unit
 
Social worker/patient navigator contact
Clinical Research Unit
 
Clinical research contact
Stephanie Badour
 
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 
Medical contact
Dr. Josee Brossard 
Social worker/patient navigator contact
Please Contact Site Directly
 
Clinical research contact
Please Contact Site Directly 
 
Medical contact
Dr. Craig Erker
Dr. Conrad Fernandez 
Dr. Ketan Kulkarni 
 
Social worker/patient navigator contact
Rhonda Brophy
 
Clinical research contact
Tina Bocking
 

 

 

Study Description

This study is looking at a new drug called selumetinib to see if it works as well as (or better than) the usual treatment (drugs called carboplatin/vincristine) for children with a type of brain tumor called low grade glioma. This study is also checking if selumetinib is better for helping improve vision for children with these tumors. Selumetinib works by blocking a substance called an enzyme that the tumor cells need to grow, which can help kill them. The regular treatment uses different drugs that stop tumor cells from growing in different ways. This study will compare to see which method is better. 

Inclusion Criteria
  • Patients must be >= 2 years and =< 21 years at the time of enrollment
  • Patients must have neurofibromatosis type 1 (NF1), newly diagnosed or have previously diagnosed NF-1 associated LGG that has not been treated with any modality other than surgery
  • Additional inclusion criteria applies for patients with optic pathway gliomas, if applicable
  • Patient must meet all of the bloodwork and organ function requirements outlined in the study
  • Patients with a known seizure disorder should be stable and should have not experienced a significant increase in seizure frequency within 2 weeks prior to enrollment
  • Patients must have an adequate performance status 
  • Patients must have the ability to swallow whole capsules
  • All patients and/or their parents or legal guardians must sign a written informed consent.

Other inclusion and exclusion criteria applies and will be discussed with you by the study team.

MK-4280-003 - A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Open

MK-4280-003 - A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants With Hematologic Malignancies

Go to Health Care Provider version

DiagnosisHodgkin Disease Lymphoma, Non-Hodgkin Lymphoma, B-CellStudy StatusOpen
PhaseI/II
Age18 Years and olderRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationBiological: Pembrolizumab (KEYTRUDA®) Administered as an IV infusion every 3 weeks (Q3W) Biological: Favezelimab (MK-4280) Administered as an IV infusion Q3W
Last Posted Update2024-08-21
ClinicalTrials.gov #NCT03598608
International Sponsor
Merck Sharp & Dohme LLC
Principal Investigators for Canadian Sites
CancerCare Manitoba - Dr. Leonard Minuk
Centres
Medical contact

Sarcoma - Dr. Sapna Oberoi

soberoi@cancercare.mb.ca

Social worker/patient navigator contact
N/A
Clinical research contact

Rebekah Hiebert

rhiebert5@cancercare.mb.ca

Kathryn Dyck

kdyck5@cancercare.mb.ca

 

 

Study Description

This study will evaluate the combination of two drugs called favezelimab and pembrolizumab to see how effective and safe it is for treating patients with a cancer called lymphoma. There are various different kinds of lymphoma, this study is for patients with classical Hodgkin, indolent non-Hodgkin or diffuse large B-cell lymphoma. 

Inclusion Criteria
  • Participants must be 18 years of age or older 
  • Participants must have a diagnosis of:
    • classical Hodgkin lymphoma (cHL)
    • diffuse large B-cell lymphoma (DLBCL)
    • indolent non-Hodgkin lymphoma (iNHL)
  • Must have a tumour that can be measured on CT or MRI 
  • Participant should be well enough to carry out light daily tasks, e.g., light house work, office work, normal activities

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

LY17 - A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Open

LY17 - A Multi-Stage Randomized Phase II Study of Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma

Go to Health Care Provider version

DiagnosisLymphomaStudy StatusOpen
PhaseII
Age16 Years to 65 YearsRandomisationYES
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationAll participants will receive the drug Rituximab (IV) and Cisplatin (IV) Depending on which participant group you are assigned, you may also receive: Drug: Gemcitabine (IV) Drug: Dexamethasone (Oral) Drug: Mesna (IV) Drug: Cyclophosphamide (IV) Drug: Etoposide (IV) Drug: G-CSF (SC) Drug: Selinexor (Oral)
Last Posted Update2024-08-21
ClinicalTrials.gov #NCT02436707
International Sponsor
Canadian Cancer Trials Group
Principal Investigators for Canadian Sites
CancerCare Manitoba - Dr. Pamela Skrabek
Centres
Medical contact

Sarcoma - Dr. Sapna Oberoi

soberoi@cancercare.mb.ca

Social worker/patient navigator contact
N/A
Clinical research contact

Rebekah Hiebert

rhiebert5@cancercare.mb.ca

Kathryn Dyck

kdyck5@cancercare.mb.ca

 

 

Study Description

The purpose of this study is to find out what effects new combinations of treatment will help in treating a cancer called lymphoma. New promising treatment strategies will be added to this study as they are available to be compared against the standard treatment.

Inclusion Criteria
  • Participants must be between 16 to 65 years old to participate
  • Participants must have one of the following diagnoses: 
    • Diffuse large cell lymphoma, B-cell (includes primary mediastinal B-cell lymphoma, T-cell rich B-cell lymphoma)
    • Previous indolent lymphoma with transformation to diffuse large B-cell lymphoma at most recent relapse
    • Unclassifiable B-cell lymphoma with indeterminate features between diffuse large B-cell lymphoma and Burkitt lymphoma
  • Participants must have the presence of a protein called CD20
  • Must meet all bloodwork requirements
  • Participants who can bare children must have a negative pregnancy test prior to starting 
  • Participants must be willing to sign a consent form and agree to the study schedule

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team. 

F8394-201 - A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Open

F8394-201 - A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations

Go to Health Care Provider version

DiagnosisCancer Harboring BRAF AlterationsStudy StatusOpen
PhaseII
Age10 Years and olderRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: Plixorafenib (Oral tablets) Drug: Cobicistat (Oral tablets)
Last Posted Update2024-08-21
ClinicalTrials.gov #NCT05503797
International Sponsor
Fore Biotherapeutics
Principal Investigators for Canadian Sites
Sunnybrook Health Sciences Centre - Dr. Mary Jane Lim-Fay
CHU Ste. Justine - Dr. Sébastien Perreault
Centres
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
 
Social worker/patient navigator contact
Marie-Claude Charrette
 
Clinical research contact
Marie Saint-Jacques
 
Medical contact
N/A
Social worker/patient navigator contact
N/A
Clinical research contact

   

 

 

Study Description

 

This study evaluates how effective a drug called plixorafenib is in participants with solid tumors or central nervous system (CNS) tumors with a genetic mutation called a BRAF fusion/BRAF V600E mutation that have progressed or come back.

Inclusion Criteria
  • Male and female, ≥10 years of age, and weighing ≥30 kg.
  • Diagnosis of a solid tumor or primary CNS tumor that has previously been treated with other standard therapies
  • Documentation of BRAF gene fusion in tumor
  • Willingness to provide informed consent and comply with study requirements 

Other inclusion and exclusion criteria apply and will be discussed with you by the study team. 

DAY101-102 - A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations (FIRELIGHT)

Closed

DAY101-102 - A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations (FIRELIGHT)

Go to Health Care Provider version

DiagnosisNon-hematological tumours (solid and brain) with relevant biomarkerStudy StatusClosed
PhaseI/II
Age12 Years and olderRandomisationNO
Line of treatmentDisease relapse or progression
Routes of Treatment AdministrationDrug: DAY101 (Oral tablet) Drug: Pimasertib Hydrochloride (Oral capsule) - Sub-study B only.
Last Posted Update2024-07-31
ClinicalTrials.gov #NCT04985604
International Sponsor
Day One Biopharmaceuticals, Inc.
Principal Investigators for Canadian Sites
The Hospital for Sick Children - Dr. Daniel Morgenstern
Centres
Medical contact

Dr. Daniel Morgenstern

daniel.morgenstern@sickkids.ca

Social worker/patient navigator contact

Karen Fung 

karen.fung@sickkids.ca

Clinical research contact

New Agent and Innovative Therapies (NAIT) 

nait.info@sickkids.ca

 

 

 

Study Description

 

This is a Phase 1b/2 study of the drug DAY101 in patients ≥12 years of age with solid tumours or brain tumours that have come back or progressed. This study includes 2 sub-studies, patients in sub-study A will receive the DAY-101 drug and patients in sub-study B will receive "DAY-101" and another drug called pimasertib in combination.

Inclusion Criteria
  • Participants must be between 12 to 18 years old
  • Participants must have a solid tumour or brain tumour that has come back (relapsed) or progressed 
  • Participants must have a qualifying gene change in the tumour (MAPK pathway)
  • If enrolled on study, patients and their families must agree to the study requirements by signing an informed consent/assent form

Other inclusion and exclusion criteria may apply and will be discussed with you by the study team.